AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7951368 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb vaccine with multiple puncture cylinder (7,000 TCID50/0.5 ml)
Number of subjects: 145
Study 7951368 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb vaccine with bifurcated needle (7,000 TCID50/0.5 ml)
Number of subjects: 145
Study 7951368 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 145
Study 3310646 — intervention group
Group type: COMPARATOR
Intervention: minus lenses with full correction for continuous use (the reference group)
Number of subjects: 240
Study 3310646 — intervention group
Group type: EXPERIMENTAL
Intervention: minus lenses with full correction for distant vision only
Number of subjects: 240
Study 3310646 — intervention group
Group type: EXPERIMENTAL
Intervention: bifocal lenses
Number of subjects: 240
Study 29791259 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information and motivational text messages)
Number of subjects: 6006
Study 29791259 — intervention group
Group type: EXPERIMENTAL
Intervention: Free cessation aids (nicotine-replacement therapy or pharmacotherapy, with e-cigarettes if standard therapies failed)
Number of subjects: 6006
Study 29791259 — intervention group
Group type: EXPERIMENTAL
Intervention: Free e-cigarettes (without requirement that standard therapies had been tried)
Number of subjects: 6006
Study 29791259 — intervention group
Group type: EXPERIMENTAL
Intervention: Free cessation aids plus $600 in rewards for sustained abstinence
Number of subjects: 6006
Study 29791259 — intervention group
Group type: EXPERIMENTAL
Intervention: Free cessation aids plus $600 in redeemable funds (money removed if cessation milestones not met)
Number of subjects: 6006
Study 29791259 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged cohort (1191 employees who actively participated)
Number of subjects: 6006
Study 26956643 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic DECT images
Number of subjects: 61
Study 26956643 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine map DECT images
Number of subjects: 61
Study 26956643 — intervention group
Group type: COMPARATOR
Intervention: Polychromatic DECT images
Number of subjects: 61
Study 25440215 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Techniques (IASTT)
Number of subjects: 49
Study 25440215 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 49
Study 22406074 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-Creatinine Ratio (PCR)
Number of subjects: 27
Study 22406074 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-Creatinine Ratio (ACR)
Number of subjects: 27
Study 22406074 — intervention group
Group type: COMPARATOR
Intervention: 24h Urine Protein
Number of subjects: 27
Study 20473055 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 237
Study 20473055 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 237
Study 18928975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic resection and coagulation of the base of endometrial polyps with focal atypia
Number of subjects: 21
Study 18928975 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 21
Study 15975991 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary balloon angioplasty (PTCA)
Number of subjects: 359
Study 15975991 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 359
Study 15975991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PTCA and CABG
Number of subjects: 359
Study 11931060 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic medial approach
Number of subjects: 30
Study 11931060 — intervention group
Group type: COMPARATOR
Intervention: Open microscopic surgical technique
Number of subjects: 30
Study 10364999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.25 mg
Number of subjects: 50
Study 10364999 — intervention group
Group type: COMPARATOR
Intervention: Epidural diamorphine 5 mg
Number of subjects: 50
Study 7863879 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mAs
Number of subjects: 30
Study 7863879 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mAs
Number of subjects: 30
Study 7863879 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mAs
Number of subjects: 30
Study 7863879 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mAs
Number of subjects: 30
Study 7863879 — intervention group
Group type: COMPARATOR
Intervention: 400 mAs
Number of subjects: 30
Study 7863879 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mAs, 140 mAs, 80 mAs, 20 mAs
Number of subjects: 30
Study 8254467 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral fluconazole once daily for 14 days
Number of subjects: 334
Study 8254467 — intervention group
Group type: COMPARATOR
Intervention: 10 mg clotrimazole five times daily for 14 days
Number of subjects: 334
Study 8254467 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral fluconazole once daily
Number of subjects: 334
Study 8254467 — intervention group
Group type: COMPARATOR
Intervention: 10 mg clotrimazole five times daily
Number of subjects: 334
Study 2879345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/Ampicillin
Number of subjects: 83
Study 2879345 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/Clindamycin
Number of subjects: 83
Study 30558330 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 g Resistant Starch (RS)
Number of subjects: 0
Study 30558330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28057126 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a (2-3 cycles)
Number of subjects: 87
Study 28057126 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a (2 cycles)
Number of subjects: 87
Study 28057126 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a (3 cycles)
Number of subjects: 87
Study 28057126 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a
Number of subjects: 87
Study 28057126 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 87
Study 24962306 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-related ergonomics intervention program
Number of subjects: 127
Study 24962306 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 23228891 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 487
Study 23228891 — intervention group
Group type: EXPERIMENTAL
Intervention: Short SANS
Number of subjects: 487
Study 23228891 — intervention group
Group type: COMPARATOR
Intervention: Original SANS
Number of subjects: 487
Study 23228891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 21574984 — intervention group
Group type: EXPERIMENTAL
Intervention: Briakinumab (200 mg at weeks 0 and 4, followed by 100 mg at week 8)
Number of subjects: 350
Study 21574984 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly at weeks 0-11)
Number of subjects: 350
Study 21574984 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 350
Study 17517409 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 4 embryo transfer
Number of subjects: 350
Study 17517409 — intervention group
Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 350
Study 16227328 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 596
Study 16227328 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 596
Study 16227328 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 596
Study 16227328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated group
Number of subjects: 596
Study 12698776 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (norelgestromin and ethinyl estradiol)
Number of subjects: 146
Study 12698776 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 146
Study 12698776 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch
Number of subjects: 146
Study 11082083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac
Number of subjects: 148
Study 11082083 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 148
Study 7575965 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopaque
Number of subjects: 29
Study 7575965 — intervention group
Group type: COMPARATOR
Intervention: Opaque P
Number of subjects: 29
Study 7575965 — intervention group
Group type: COMPARATOR
Intervention: Vita-VMK-Paint-On 88
Number of subjects: 29
Study 2277761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 16
Study 2277761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7030901 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion (35 mEq/5h)
Number of subjects: 23
Study 7030901 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 23
Study 31834098 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 2 mg
Number of subjects: 21
Study 31834098 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 4 mg
Number of subjects: 21
Study 31834098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31834098 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 2 mg and 4 mg
Number of subjects: 21
Study 31834098 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 21
Study 31151335 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB) with isobaric bupivacaine 0.5% (0.3 mL/kg) and dexmedetomidine (1 mcg/kg) - Group II
Number of subjects: 60
Study 31151335 — intervention group
Group type: COMPARATOR
Intervention: Thoracic paravertebral block (PVB) with isobaric bupivacaine 0.5% (0.3 mL/kg) - Group I
Number of subjects: 60
Study 29155861 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented pancreatic enzymes
Number of subjects: 0
Study 26544974 — intervention group
Group type: EXPERIMENTAL
Intervention: New item response model (extension of the binomial error model)
Number of subjects: 0
Study 26544974 — intervention group
Group type: EXPERIMENTAL
Intervention: New item response model
Number of subjects: 0
Study 23324710 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 0
Study 23324710 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone intervention
Number of subjects: 0
Study 23324710 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study 22269234 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries detector dye
Number of subjects: 45
Study 22269234 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 45
Study 22269234 — intervention group
Group type: COMPARATOR
Intervention: Mechanical (conventional technique)
Number of subjects: 45
Study 19499659 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA-TCI with propofol (Cpi = 4 microg/ml) and remifentanil
Number of subjects: 70
Study 19499659 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 70
Study 17343103 — intervention group
Group type: EXPERIMENTAL
Intervention: New cardiovascular drugs without clinical trial outcome data
Number of subjects: 0
Study 17343103 — intervention group
Group type: COMPARATOR
Intervention: Similar drugs with clinical trial outcome data
Number of subjects: 0
Study 15194628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle manoeuvre
Number of subjects: 68
Study 15194628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning before the Pringle manoeuvre
Number of subjects: 68
Study 15194628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 68
Study 15194628 — intervention group
Group type: COMPARATOR
Intervention: Without pedicle clamping
Number of subjects: 68
Study 10666751 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI pacing at 70 beats/min (test A)
Number of subjects: 15
Study 10666751 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI pacing matched to intrinsic heart rate (95 +/- 11 beats/min) (test B)
Number of subjects: 15
Study 9059545 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral losartan
Number of subjects: 9
Study 8198030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin, 0.6 mg/hour
Number of subjects: 22
Study 8198030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3556123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg b.d.
Number of subjects: 140
Study 3556123 — intervention group
Group type: COMPARATOR
Intervention: Augmentin 375 mg t.d.s.
Number of subjects: 140
Study 3556123 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg t.d.s.
Number of subjects: 140
Study 30741081 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band exercise (45-60 min per session, 3 days a week for 8 weeks)
Number of subjects: 70
Study 30741081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 70
Study 30327403 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise referral schemes enhanced by self-management strategies
Number of subjects: 0
Study 30327403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-utility analysis using EQ-5D-5L
Number of subjects: 0
Study 30327403 — intervention group
Group type: EXPERIMENTAL
Intervention: Capability well-being measured using ICECAP-O
Number of subjects: 0
Study 30327403 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare costs (hospitalisations, emergency visits, appointments)
Number of subjects: 0
Study 30327403 — intervention group
Group type: EXPERIMENTAL
Intervention: Social care costs (community care)
Number of subjects: 0
Study 30327403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-consequence analysis
Number of subjects: 0
Study 28961905 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 250 mg twice daily
Number of subjects: 577
Study 28961905 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times daily
Number of subjects: 577
Study 26182747 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment for peripheral vascular disease
Number of subjects: 25
Study 26182747 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment for tibioperoneal lesions
Number of subjects: 25
Study 26182747 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment for carotid lesions
Number of subjects: 25
Study 23749840 — intervention group
Group type: EXPERIMENTAL
Intervention: Arikace 560 mg
Number of subjects: 105
Study 23749840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 20472124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 53
Study 20472124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 18977243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Internet-plus-email intervention (access to a tailored website and weekly emails)
Number of subjects: 156
Study 18977243 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 156
Study 16331118 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 801
Study 16331118 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg
Number of subjects: 801
Study 16331118 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg
Number of subjects: 801
Study 12652454 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae infection
Number of subjects: 0
Study 12652454 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies and animal models
Number of subjects: 0
Study 12652454 — intervention group
Group type: EXPERIMENTAL
Intervention: Human intervention studies
Number of subjects: 0
Study 10830757 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 10830757 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 60
Study 8971618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic azithromycin
Number of subjects: 654
Study 8971618 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic azithromycin)
Number of subjects: 654
Study 1281442 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial allergen extracts
Number of subjects: 17
Study 1281442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh, standardized foods
Number of subjects: 17
Study 2579462 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcuticular absorbable (Dexon) suture
Number of subjects: 205
Study 31570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass method of dosing epinephrine (milligrams per kilogram)
Number of subjects: 70
Study 31570509 — intervention group
Group type: COMPARATOR
Intervention: Volume method of dosing epinephrine (milliliters per kilogram)
Number of subjects: 70
Study 31570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass method doses
Number of subjects: 70
Study 31570509 — intervention group
Group type: COMPARATOR
Intervention: Volume method doses
Number of subjects: 70
Study 31570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 70
Study 29616285 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated TKA
Number of subjects: 122
Study 29616285 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 122
Study 27441950 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized muscle fatigue (LMF) induced using a custom fatigue protocol with plantar-flexion and dorsiflexion exertions at 12 cycles per minute at isotonic loads of 70% and 30% of individual maximal voluntary isometric strength.
Number of subjects: 22
Study 27441950 — intervention group
Group type: COMPARATOR
Intervention: Localized muscle fatigue (LMF) induced using a custom fatigue protocol.
Number of subjects: 22
Study 25416537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention through a training program for picture book reading
Number of subjects: 58
Study 25416537 — intervention group
Group type: COMPARATOR
Intervention: Control group (lectures about elderly health maintenance)
Number of subjects: 58
Study 25416537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention for participants with mild cognitive impairment (MCI)
Number of subjects: 58
Study 23155344 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA group (omega-3 fish oil lipid emulsion)
Number of subjects: 66
Study 23155344 — intervention group
Group type: COMPARATOR
Intervention: PN group
Number of subjects: 66
Study 19156679 — intervention group
Group type: EXPERIMENTAL
Intervention: Warned malingerers
Number of subjects: 67
Study 19156679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwarned malingerers
Number of subjects: 67
Study 19156679 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 67
Study 17179910 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg hydrotalcite
Number of subjects: 53
Study 17179910 — intervention group
Group type: COMPARATOR
Intervention: 10 mg famotidine
Number of subjects: 53
Study 15726880 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (Traconal 100 mg)
Number of subjects: 24
Study 11868919 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 11868919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9797644 — intervention group
Group type: EXPERIMENTAL
Intervention: Running training for 13 weeks
Number of subjects: 14
Study 9797644 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained usual lifestyle)
Number of subjects: 14
Study 9797644 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners after 9 days of detraining
Number of subjects: 14
Study 9797644 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial lipaemia and post‐heparin LPL activity
Number of subjects: 14
Study 7667348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) at 20% concentration
Number of subjects: 10
Study 7667348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) at 30% concentration
Number of subjects: 10
Study 7667348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) at 40% concentration
Number of subjects: 10
Study 7667348 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (N2O) at 0% concentration (control)
Number of subjects: 10
Study 2669565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk whey hydrolysate formula (NAN/HA)
Number of subjects: 72
Study 2669565 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cow milk formula (Similac)
Number of subjects: 72
Study 2669565 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula (Isomil)
Number of subjects: 72
Study 2669565 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breast feeding for greater than or equal to 4 months
Number of subjects: 72
Study 5443385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentazocine 30 mg
Number of subjects: 15
Study 5443385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentazocine 60 mg
Number of subjects: 15
Study 30472970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app with vegetable-based recipes and food tips
Number of subjects: 289
Study 28631827 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 199
Study 28631827 — intervention group
Group type: COMPARATOR
Intervention: Colonic resection
Number of subjects: 199
Study 25926015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch helical scan first
Number of subjects: 303
Study 25926015 — intervention group
Group type: COMPARATOR
Intervention: Conventional scan first
Number of subjects: 303
Study 22607734 — intervention group
Group type: EXPERIMENTAL
Intervention: Long DRD4 allele carriers (seven or greater tandem repeats)
Number of subjects: 0
Study 22607734 — intervention group
Group type: EXPERIMENTAL
Intervention: Long DRD4 allele
Number of subjects: 0
Study 22607734 — intervention group
Group type: COMPARATOR
Intervention: Short DRD4 homozygotes
Number of subjects: 0